• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

steven.tong@unimelb.edu.au

Credentials


Position
Clinical Professorial Fellow
Department of Infectious Diseases
Education
PhD
Charles Darwin Univeristy
Bachelors Degree (Honours)
University of Melbourne
ORCID

0000-0002-1368-8356

Prof Steven Tong

Clinical Professorial Fellow
Department of Infectious Diseases

496 Scholarly works
48 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Communicable episode 45: top infectious diseases papers in 2025
    DOI: 10.1016/j.cmicom.2026.105203
  • 2026

    Journal article

    Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial
    DOI: 10.1016/S0140-6736(26)00761-0
  • 2026

    Journal article

    Flucloxacillin plasma and urinary concentrations with and without probenecid and urinary biomarker profiles in healthy volunteers.
    DOI: 10.1002/bcp.70663
  • 2026

    Journal article

    An Achilles' heel for methicillin-resistant Staphylococcus aureus? Re-evaluating β-lactam susceptibility of MRSA.
    DOI: 10.1128/aac.00374-26
  • 2025

    Research grants (ARC, NHMRC, MRFF)

    The Staphylococcus Aureus Network Adaptive Platform (SNAP) Trial
  • 2025

    Research grants (ARC, NHMRC, MRFF)

    Promoat: An Adaptive Platform Trial of Antibiotic Therapy to Improve Outcomes From Preterm Prelabour Rupture of Membranes
  • 2020

    Research grants (ARC, NHMRC, MRFF)

    The Staphylococcus Aureus Network Adaptive Platform Trial
Steven Tong

Latest Honours,
Awards and Fellowships


2006
Fellow of the Royal Australasian College of Physicians (FRACP)

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.
    DOI: 10.1093/cid/ciag387
  • 2026

    Journal article

    Towards use of Patient-informed Relevant Outcomes (PRO) in trials of bloodstream infections: a mixed-methods study protocol (BALANCE PRO).
    DOI: 10.1136/bmjopen-2026-119849
  • 2026

    Journal article

    A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.
    DOI: 10.1093/jac/dkag215
  • 2026

    Journal article

    Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population
    DOI: 10.5694/mja2.70241
  • 2026

    Journal article

    Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).
    DOI: 10.1097/CCM.0000000000007134
  • 2026

    Journal article

    Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia
    DOI: 10.1056/NEJMoa2506905

RECENT PROJECTS

  • 2025

    Research grants (ARC, NHMRC, MRFF)

    STReptococcal Adaptive Platform Trial (STRAP)
  • 2024

    Research grants (ARC, NHMRC, MRFF)

    Laboratory Detection and Clinical Significance of the Cefazolin Inoculum Effect for Staphylococcus Aureus Bloodstream Infections

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224